866-997-4948(US-Canada Toll Free)

Advanced Malignancy Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Nov 2012

Category :

Oncology

No. of Pages : 675 Pages


Global Markets Directs, \'Advanced Malignancy Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Advanced Malignancy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Advanced Malignancy. 

Advanced Malignancy Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Advanced Malignancy.
  • A review of the Advanced Malignancy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Advanced Malignancy pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Advanced Malignancy.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Advanced Malignancy pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 9
List of Figures 15
Introduction 17
Global Markets Direct Report Coverage 17
Advanced Malignancy Overview 18
Therapeutics Development 19
An Overview of Pipeline Products for Gastric Cancer 19
Gastric Cancer Therapeutics under Development by Companies 21
Gastric Cancer Therapeutics under Investigation by Universities/Institutes 38
Late Stage Products 53
Comparative Analysis 53
Mid Clinical Stage Products 54
Comparative Analysis 54
Early Clinical Stage Products 55
Comparative Analysis 55
Discovery and Pre-Clinical Stage Products 56
Comparative Analysis 56
Advanced Malignancy Therapeutics Products under Development by Companies 57
Advanced Malignancy Therapeutics Products under Investigation by Universities/Institutes 105
Companies Involved in Gastric Cancer Therapeutics Development 151
Bristol-Myers Squibb Company 151
Genzyme Corporation 152
Baxter International Inc. 153
Boehringer Ingelheim GmbH 154
F. Hoffmann-La Roche Ltd. 155
Kyowa Hakko Kirin Co., Ltd. 156
Abbott Laboratories 157
Biogen Idec Inc. 158
Amgen Inc. 159
Sanofi-Aventis 160
Adherex Technologies Inc. 161
AstraZeneca PLC 162
Eli Lilly and Company 163
GlaxoSmithKline plc 164
Seattle Genetics, Inc. 165
Tekmira Pharmaceuticals Corp. 166
Genentech, Inc. 167
MedImmune LLC 168
Isis Pharmaceuticals, Inc. 169
Daiichi Sankyo Company, Ltd 170
Merck & Co., Inc. 171
Esperance Pharmaceuticals, Inc. 304
Etubics Corporation 305
Immunocore Limited. 306
BIND Biosciences, Inc. 307
Tragara Pharmaceuticals, Inc. 308
Drais Pharmaceuticals, Inc. 309
Cellceutix Corporation 310
PharmaMar, S.A. 311
VentiRx Pharmaceuticals, Inc. 312
AB Science 313
Kinex Pharmaceuticals, LLC 314
Adamis Pharmaceuticals Corporation 315
Tigris Pharmaceuticals, Inc. 316
Celtic Biotech, Ltd. 317
Cylene Pharmaceuticals, Inc. 318
Genelux Corporation 319
Biothera 320
Nereus Pharmaceuticals, Inc. 321
Viventia Biotechnologies Inc. 322
AVEO Pharmaceuticals, Inc. 323
TRACON Pharmaceuticals, Inc. 324
Pierre Fabre Medicament 325
Perseus Proteomics, Inc. 326
Clovis Oncology, Inc. 327
Amplimmune, Inc. 328
PharmAbcine, Inc. 329
Pathway Therapeutics Limited 330
PNP Therapeutics, Inc. 331
Zenyaku Kogyo Co., Ltd. 332
BioProspecting NB, Inc. 333
Aragon Pharmaceuticals, Inc. 334
RECEPTA Biopharma S.A. 335
Vakzine Projekt Management GmbH 336
NuCana BioMed Limited 337
Polaris Group 338
Eurofarma 339
XBiotech USA, Inc. 340
DEKK-TEC, Inc. 341
Agennix AG 342
Regulon Inc. 343
Acacia Pharma Ltd. 344
Gradalis Inc. 345
SentoClone AB 346
Oncozyme Pharma Inc. 347
Biotech Pharmaceuticals Co., Ltd. 348
Gastric Cancer Therapeutics Assessment 349
Assessment by Monotherapy Products 349
Assessment by Combination Products 350
Assessment by Route of Administration 351
Assessment by Molecule Type 353
Drug Profiles 355
perifosine - Drug Profile 355
motesanib diphosphate - Drug Profile 358
brivanib alaninate - Drug Profile 360
trastuzumab - Drug Profile 362
linifanib - Drug Profile 365
vismodegib - Drug Profile 367
brentuximab vedotin - Drug Profile 370
fulvestrant - Drug Profile 373
yttrium Radiotherapy - Drug Profile 375
canfosfamide hydrochloride - Drug Profile 377
YN-968D1 - Drug Profile 379
AGS-003 - Drug Profile 381
Docetaxel + S-1 - Drug Profile 383
Perifosine + Xeloda - Drug Profile 384
Docetaxel + Prednisone + Atrasentan - Drug Profile 386
trabectedin - Drug Profile 388
Fulvestrant + Lapatinib - Drug Profile 390
Oxaliplatin + Capecitabine + Radiation Therapy - Drug Profile 391
cisplatin - Drug Profile 393
Torisel + Bevacizumab - Drug Profile 394
memantine - Drug Profile 397
Panitumumab - Drug Profile 398
bevacizumab + pemetrexed + cisplatin - Drug Profile 399
Capecitabine + Gemcitabine - Drug Profile 400
Gemcitabine + Capecitabine + Radiation Therapy - Drug Profile 401
Androgen suppression + Zoledronate - Drug Profile 403
Paclitaxel + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile 404
Docetaxel + Cisplatin + Hydroxyurea + 5-Fluorouracil - Drug Profile 406
Capecitabine + Bevacizumab - Drug Profile 409
Cetuximab + Radiation Therapy - Drug Profile 410
TV-1011 + Docetaxel - Drug Profile 411
Sunitinib + Erlotinib - Drug Profile 413
AMG 706 + Paclitaxel + Carboplatin - Drug Profile 414
Faslodex + Arimidex - Drug Profile 416
Zactima + Taxotere - Drug Profile 417
Oxaliplatin + Leucovorin + Fluorouracil + Irinotecan - Drug Profile 419
Aflibercept + Docetaxel - Drug Profile 421
Larotaxel + Cisplatin - Drug Profile 423
Vinflunine + Capecitabine - Drug Profile 425
CCI-779 + Interferon Alfa - Drug Profile 426
afatinib - Drug Profile 427
Zactima + Alimta - Drug Profile 429
Capecitabine + Oxaliplatin + Radiation Therapy - Drug Profile 431
Taxotere + Cisplatin + Fluorouracil - Drug Profile 433
XRP6976 + Oxaliplatin + S-1 - Drug Profile 435
Tarceva + MetMAb - Drug Profile 437
Tykerb + Paclitaxel - Drug Profile 438
Treanda + Rituxan - Drug Profile 440
Vargatef + Docetaxel - Drug Profile 442
Vargatef + Pemetrexed - Drug Profile 446
masitinib - Drug Profile 448
melatonin - Drug Profile 450
bevacizumab + gemcitabine + cisplatin - Drug Profile 451
TH-302 + Doxorubicin - Drug Profile 453
FOLFOX - Drug Profile 455
S-1 + Cisplatin - Drug Profile 456
Octreotide + Bevacizumab - Drug Profile 458
capecitabine - Drug Profile 460
Gemcitabine + TS-1 - Drug Profile 461
Sunitinib - Drug Profile 463
ifosfamide - Drug Profile 465
XP + Simvastatin - Drug Profile 466
Docetaxel + Cisplatin - Drug Profile 467
AB-1010 + Gemcitabine - Drug Profile 468
Gemcitabine + Tegafur + Gimeracil + Oteracil Potassium - Drug Profile 470
S-1 + Oxaliplatin - Drug Profile 471
Taxotere + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 473
OTS-102 + Gemcitabine - Drug Profile 475
doxorubicin + carboplatin - Drug Profile 476
Cyclophosphamide + Methotrexate + 5-Fluorouracil - Drug Profile 477
Gemcitabine + Tegafur + Gimeracil + Oteracil Potassium - Drug Profile 479
irinotecan hydrochloride - Drug Profile 481
Xelox - Drug Profile 482
BV-NSCLC-001 - Drug Profile 483
Ixempra - Drug Profile 484
Adriamycin + Cyclophosphamide + Vincristine + Methotrexate + Fluorouracil - Drug Profile 485
Cyclophosphamide + Methotrexate + Fluorouracil + Prednisone - Drug Profile 487
Thalidomide + TACE - Drug Profile 489
cyclophosphamide - Drug Profile 490
Herceptin + Taxotere - Drug Profile 491
Floxuridine + Dexamethasone + Leucovorin - Drug Profile 493
Bevacizumab + Cetuximab + Fluorouracil + Irinotecan Hydrochloride + Leucovorin Calcium + Oxaliplatin - Drug Profile 495
Cisplatin - Drug Profile 499
Cisplatin + Paclitaxel - Drug Profile 500
YN-968D1 - Drug Profile 501
Nexavar + Capecitabine - Drug Profile 502
Bevacizumab + Letrozole - Drug Profile 504
levosimendan - Drug Profile 505
Everolimus + Octreotide Depot - Drug Profile 506
Nimotuzumab - Drug Profile 508
Talactoferrin + Carboplatin + Paclitaxel - Drug Profile 510
Nimotuzumab + Cisplatin - Drug Profile 512
gemcitabine - Drug Profile 513
RG7159 + Chemotherapy - Drug Profile 514
Gemcitabine + Capecitabine + Telovac + Sargramostim - Drug Profile 516
Debio 8206 SC - Drug Profile 518
Paclitaxel + Carboplatin + Cisplatin - Drug Profile 519
Pertuzumab + Herceptin + Paclitaxel - Drug Profile 521
Pertuzumab + Herceptin + Nab-paclitaxel - Drug Profile 523
BKM-120 + [fulvestrant] - Drug Profile 525
Pemetrexed Disodium + Cisplatin + Gemcitabine - Drug Profile 526
Metformin + Taxane - Drug Profile 528
Lipoplatin + Gemcitabine - Drug Profile 529
Advanced Malignancy Therapeutics Drug Profile Updates 530
Advanced Malignancy Therapeutics Discontinued Products 570
Advanced Malignancy Therapeutics - Dormant Products 586
Gastric Cancer Product Development Milestones 658
Featured News & Press Releases 658

Appendix 667
Methodology 667
Coverage 667
Secondary Research 667
Primary Research 667
Expert Panel Validation 667
Contact Us 668
Disclaimer 668

List of Table


Number of Products Under Development for Gastric Cancer, H2 2012 26
Products under Development for Gastric Cancer Comparative Analysis, H2 2012 27
Number of Products under Development by Companies, H2 2012 29
Number of Products under Development by Companies, H2 2012 (Contd..1) 30
Number of Products under Development by Companies, H2 2012 (Contd..2) 31
Number of Products under Development by Companies, H2 2012 (Contd..3) 32
Number of Products under Development by Companies, H2 2012 (Contd..4) 33
Number of Products under Development by Companies, H2 2012 (Contd..5) 34
Number of Products under Development by Companies, H2 2012 (Contd..6) 35
Number of Products under Development by Companies, H2 2012 (Contd..7) 36
Number of Products under Development by Companies, H2 2012 (Contd..8) 37
Number of Products under Development by Companies, H2 2012 (Contd..9) 38
Number of Products under Development by Companies, H2 2012 (Contd..10) 39
Number of Products under Development by Companies, H2 2012 (Contd..11) 40
Number of Products under Development by Companies, H2 2012 (Contd..12) 41
Number of Products under Development by Companies, H2 2012 (Contd..13) 42
Number of Products under Development by Companies, H2 2012 (Contd..14) 43
Number of Products under Development by Companies, H2 2012 (Contd..15) 44
Number of Products under Investigation by Universities/Institutes, H2 2012 46
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 47
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 48
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 49
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 50
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 51
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 52
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 53
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 54
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 55
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 56
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 57
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 58
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 59
Comparative Analysis by Late Stage Development, H2 2012 60
Comparative Analysis by Mid Clinical Stage Development, H2 2012 61
Comparative Analysis by Early Clinical Stage Development, H2 2012 62
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 63
Products under Development by Companies, H2 2012 64
Products under Development by Companies, H2 2012 (Contd..1) 65
Products under Development by Companies, H2 2012 (Contd..2) 66
Products under Development by Companies, H2 2012 (Contd..3) 67
Products under Development by Companies, H2 2012 (Contd..4) 68
Products under Development by Companies, H2 2012 (Contd..5) 69
Products under Development by Companies, H2 2012 (Contd..6) 70
Products under Development by Companies, H2 2012 (Contd..7) 71
Products under Development by Companies, H2 2012 (Contd..8) 72
Products under Development by Companies, H2 2012 (Contd..9) 73
Products under Development by Companies, H2 2012 (Contd..10) 74
Products under Development by Companies, H2 2012 (Contd..11) 75
Products under Development by Companies, H2 2012 (Contd..12) 76
Products under Development by Companies, H2 2012 (Contd..13) 77
Products under Development by Companies, H2 2012 (Contd..14) 78
Products under Development by Companies, H2 2012 (Contd..15) 79
Products under Development by Companies, H2 2012 (Contd..16) 80
Products under Development by Companies, H2 2012 (Contd..17) 81
Products under Development by Companies, H2 2012 (Contd..18) 82
Products under Development by Companies, H2 2012 (Contd..19) 83
Products under Development by Companies, H2 2012 (Contd..20) 84
Products under Development by Companies, H2 2012 (Contd..21) 85
Products under Development by Companies, H2 2012 (Contd..22) 86
Products under Development by Companies, H2 2012 (Contd..23) 87
Products under Development by Companies, H2 2012 (Contd..24) 88
Products under Development by Companies, H2 2012 (Contd..25) 89
Products under Development by Companies, H2 2012 (Contd..26) 90
Products under Development by Companies, H2 2012 (Contd..27) 91
Products under Development by Companies, H2 2012 (Contd..28) 92
Products under Development by Companies, H2 2012 (Contd..29) 93
Products under Development by Companies, H2 2012 (Contd..30) 94
Products under Development by Companies, H2 2012 (Contd..31) 95
Products under Development by Companies, H2 2012 (Contd..32) 96
Products under Development by Companies, H2 2012 (Contd..33) 97
Products under Development by Companies, H2 2012 (Contd..34) 98
Products under Development by Companies, H2 2012 (Contd..35) 99
Products under Development by Companies, H2 2012 (Contd..36) 100
Products under Development by Companies, H2 2012 (Contd..37) 101
Products under Development by Companies, H2 2012 (Contd..38) 102
Products under Development by Companies, H2 2012 (Contd..39) 103
Products under Development by Companies, H2 2012 (Contd..40) 104
Products under Development by Companies, H2 2012 (Contd..41) 105
Products under Development by Companies, H2 2012 (Contd..42) 106
Products under Development by Companies, H2 2012 (Contd..43) 107
Products under Development by Companies, H2 2012 (Contd..44) 108
Products under Development by Companies, H2 2012 (Contd..45) 109
Products under Development by Companies, H2 2012 (Contd..46) 110
Products under Development by Companies, H2 2012 (Contd..47) 111
Products under Investigation by Universities/Institutes, H2 2012 112
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 113
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 114
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 115
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 116
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 117
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 118
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 119
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 120
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 121
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 122
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 123
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 124
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 125
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 126
Products under Investigation by Universities/Institutes, H2 2012 (Contd..15) 127
Products under Investigation by Universities/Institutes, H2 2012 (Contd..16) 128
Products under Investigation by Universities/Institutes, H2 2012 (Contd..17) 129
Products under Investigation by Universities/Institutes, H2 2012 (Contd..18) 130
Products under Investigation by Universities/Institutes, H2 2012 (Contd..19) 131
Products under Investigation by Universities/Institutes, H2 2012 (Contd..20) 132
Products under Investigation by Universities/Institutes, H2 2012 (Contd..21) 133
Products under Investigation by Universities/Institutes, H2 2012 (Contd..22) 134
Products under Investigation by Universities/Institutes, H2 2012 (Contd..23) 135
Products under Investigation by Universities/Institutes, H2 2012 (Contd..24) 136
Products under Investigation by Universities/Institutes, H2 2012 (Contd..25) 137
Products under Investigation by Universities/Institutes, H2 2012 (Contd..26) 138
Products under Investigation by Universities/Institutes, H2 2012 (Contd..27) 139
Products under Investigation by Universities/Institutes, H2 2012 (Contd..28) 140
Products under Investigation by Universities/Institutes, H2 2012 (Contd..29) 141
Products under Investigation by Universities/Institutes, H2 2012 (Contd..30) 142
Products under Investigation by Universities/Institutes, H2 2012 (Contd..31) 143
Products under Investigation by Universities/Institutes, H2 2012 (Contd..32) 144
Products under Investigation by Universities/Institutes, H2 2012 (Contd..33) 145
Products under Investigation by Universities/Institutes, H2 2012 (Contd..34) 146
Products under Investigation by Universities/Institutes, H2 2012 (Contd..35) 147
Products under Investigation by Universities/Institutes, H2 2012 (Contd..36) 148
Products under Investigation by Universities/Institutes, H2 2012 (Contd..37) 149
Products under Investigation by Universities/Institutes, H2 2012 (Contd..38) 150
Products under Investigation by Universities/Institutes, H2 2012 (Contd..39) 151
Products under Investigation by Universities/Institutes, H2 2012 (Contd..40) 152
Products under Investigation by Universities/Institutes, H2 2012 (Contd..41) 153
Products under Investigation by Universities/Institutes, H2 2012 (Contd..42) 154
Products under Investigation by Universities/Institutes, H2 2012 (Contd..43) 155
Products under Investigation by Universities/Institutes, H2 2012 (Contd..44) 156
Products under Investigation by Universities/Institutes, H2 2012 (Contd..45) 157
Bristol-Myers Squibb Company, H2 2012 158
F. Hoffmann-La Roche Ltd., H2 2012 162
Abbott Laboratories, H2 2012 164
Amgen Inc., H2 2012 166
Sanofi-Aventis, H2 2012 167
AstraZeneca PLC, H2 2012 169
Eli Lilly and Company, H2 2012 170
GlaxoSmithKline plc, H2 2012 171
Tekmira Pharmaceuticals Corp., H2 2012 173
AbGenomics International, Inc., H2 2012 179
YM BioSciences Inc., H2 2012 184
Novartis AG, H2 2012 190
Astellas Pharma Inc., H2 2012 193
Eisai Co., Ltd., H2 2012 197
Pfizer Inc., H2 2012 202
Taiho Pharmaceutical Co., Ltd., H2 2012 205
Yakult Honsha Co., Ltd., H2 2012 207
Exelixis, Inc., H2 2012 211
Celgene Corporation, H2 2012 213
Merck KGaA, H2 2012 219
IMMUNOMEDICS, INC, H2 2012 227
Curis, Inc., H2 2012 241
ARQULE, INC, H2 2012 244
ADVENTRX Pharmaceuticals, H2 2012 245
OncoTherapy Science, Inc., H2 2012 258
Jiangsu Hengrui Medicine Co., Ltd., H2 2012 259
NanoCarrier Co., Ltd., H2 2012 262
Rexahn Pharmaceuticals, Inc., H2 2012 263

List of Chart


Number of Products under Development for Gastric Cancer, H2 2012 26
Products under Development for Gastric Cancer Comparative Analysis, H2 2012 27
Products under Development by Companies, H2 2012 28
Products under Investigation by Universities/Institutes, H2 2012 45
Late Stage Products, H2 2012 60
Mid Clinical Stage Products, H2 2012 61
Early Clinical Stage Products, H2 2012 62
Discovery and Pre-Clinical Stage Products, H2 2012 63
Assessment by Monotherapy Products, H2 2012 356
Assessment by Combination Products, H2 2012 357
Assessment by Route of Administration, H2 2012 358
Assessment by Stage and Route of Administration, H2 2012 359
Assessment by Molecule Type, H2 2012 360
Assessment by Stage and Molecule Type, H2 2012 361

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *